The Experts below are selected from a list of 27 Experts worldwide ranked by ideXlab platform
Virgil F. Fairbanks - One of the best experts on this subject based on the ideXlab platform.
-
Hereditary red blood cell Disorders in middle eastern patients.
Mayo Clinic proceedings, 2001Co-Authors: David P. Steensma, James D. Hoyer, Virgil F. FairbanksAbstract:Hereditary Disorders of Erythrocytes are common in many areas of the world, including the Middle East. In some regions of the Middle East more than 10% of the population are carriers of a gene for one of these conditions. When patients from the Middle East seek medical care in the West, an unrecognized but clinically important Erythrocyte Disorder can result in serious complications during routine medical care, such as a drug-induced hemolytic crisis. This article reviews the most important and most common inherited red blood cell Disorders in Middle Eastern patients, including glucose-6-phosphate dehydrogenase deficiency, the thalassemias, and sickle cell Disorders. We discuss when to suspect such conditions, how to determine their presence, and how to avoid potential complications related to them. Although a detailed discussion of treatment of Erythrocyte Disorders is beyond the scope of this article, some general management principles are described.
David P. Steensma - One of the best experts on this subject based on the ideXlab platform.
-
Hereditary red blood cell Disorders in middle eastern patients.
Mayo Clinic proceedings, 2001Co-Authors: David P. Steensma, James D. Hoyer, Virgil F. FairbanksAbstract:Hereditary Disorders of Erythrocytes are common in many areas of the world, including the Middle East. In some regions of the Middle East more than 10% of the population are carriers of a gene for one of these conditions. When patients from the Middle East seek medical care in the West, an unrecognized but clinically important Erythrocyte Disorder can result in serious complications during routine medical care, such as a drug-induced hemolytic crisis. This article reviews the most important and most common inherited red blood cell Disorders in Middle Eastern patients, including glucose-6-phosphate dehydrogenase deficiency, the thalassemias, and sickle cell Disorders. We discuss when to suspect such conditions, how to determine their presence, and how to avoid potential complications related to them. Although a detailed discussion of treatment of Erythrocyte Disorders is beyond the scope of this article, some general management principles are described.
J. D. Bessman - One of the best experts on this subject based on the ideXlab platform.
-
Asymptomatic Erythrocyte Disorder Presenting as Increased Porphobilinogen Deaminase and Uroporphyrinogen Decarboxylase
Clinical Chemistry, 1995Co-Authors: Karl E. Anderson, Douglas E. Goeger, J. D. BessmanAbstract:Hematocrit,% Reticulocytes, % Erythrocyte porphobilinogen deaminase and uroporphyrinogen decarboxylase were measured as previously described (5, 6) by using porphobilinogen and pentacarboxylporphyrinogen I, respectively, as substrates. CV5 for these assays in this laboratory are 8.3% and 14.2%, respectively. rocytes,it is possible that detection of these diseases could be compromised when coexisting conditions or interventions stimulate erythropoiesis. It will be of interest, for example, to determine if Erythrocyte uroporphyrinogen decarboxylase increases during therapeutic phlebotomy in patients with porphyria cutanea tarda. The intent of this therapy, which is effective in both inherited and acquired forms of porphyria cutanea tarda, is to stimulate erythropoiesis and thereby utilize and reduce iron stores. If phlebotomy does increase Erythrocyte uroporphyrinogen decarboxylase, it might be recommended that the enzyme activity be measured before institution of phlebotomy.
James D. Hoyer - One of the best experts on this subject based on the ideXlab platform.
-
Hereditary red blood cell Disorders in middle eastern patients.
Mayo Clinic proceedings, 2001Co-Authors: David P. Steensma, James D. Hoyer, Virgil F. FairbanksAbstract:Hereditary Disorders of Erythrocytes are common in many areas of the world, including the Middle East. In some regions of the Middle East more than 10% of the population are carriers of a gene for one of these conditions. When patients from the Middle East seek medical care in the West, an unrecognized but clinically important Erythrocyte Disorder can result in serious complications during routine medical care, such as a drug-induced hemolytic crisis. This article reviews the most important and most common inherited red blood cell Disorders in Middle Eastern patients, including glucose-6-phosphate dehydrogenase deficiency, the thalassemias, and sickle cell Disorders. We discuss when to suspect such conditions, how to determine their presence, and how to avoid potential complications related to them. Although a detailed discussion of treatment of Erythrocyte Disorders is beyond the scope of this article, some general management principles are described.
Darlene A. Calhoun - One of the best experts on this subject based on the ideXlab platform.
-
Resistance to Recombinant Human Granulocyte Colony-Stimulating Factor in Neonatal Alloimmune Neutropenia Associated With Anti-Human Neutrophil Antigen-2a (NB1) Antibodies
Pediatrics, 2002Co-Authors: Akhil Maheshwari, Robert D. Christensen, Darlene A. CalhounAbstract:Neonatal alloimmune neutropenia is the neutrophil counterpart of the Erythrocyte Disorder of hemolytic disease of the newborn. Fetal neutrophil antigens, which are inherited from the father but foreign to the pregnant mother, provoke the formation of maternal antibodies, which, on transplacental passage, cause fetal/neonatal neutropenia. Because infants with this Disorder are at a higher risk of infection, recombinant hematopoietic growth factors, such as recombinant human granulocyte colony-stimulating factor, have been tried, with generally good results, to treat those with severe and prolonged neutropenia. We report a neonate who had neonatal alloimmune neutropenia associated with antibodies directed against human neutrophil antigen-2a (NB1) and initially failed to respond to even very high doses of recombinant human granulocyte colony-stimulating factor but eventually had a therapeutic response.